MTOR and glioblastoma: To gain additional evidence for the observed difference in immune cell composition between the tumour groups being driven by mTOR signalling in TAM‐MG, we looked at the signalling activity of TAM‐MG compared to TAM‐BMDM in GBM from group 1.